Combined EGFR and c-Src antisense oligodeoxynucleotides encapsulated with PAMAM Denderimers inhibit HT-29 colon...

Area of Science:

• Oncology
• Molecular Biology
• Nanotechnology

Background:

• Colon cancer remains a significant health concern, necessitating novel therapeutic strategies.
• Epidermal Growth Factor Receptor (EGFR) and c-Src are key proto-oncogenes driving colon cancer progression.
• Simultaneous targeting of EGFR and c-Src holds theoretical therapeutic potential.

Purpose of the Study:

• To develop and evaluate a nano-drug formulation combining anti-EGFR and c-Src antisense oligodeoxynucleotides for colon cancer therapy.
• To assess the cellular uptake, gene expression modulation, and antiproliferative effects of the nano-drug in colon cancer cells.

Main Methods:

• Antisense oligodeoxynucleotides targeting EGFR and c-Src were encapsulated in PAMAM dendrimers.
• Cellular uptake was confirmed using flow cytometry and fluorescence microscopy.
• Gene expression (EGFR, c-Src, STAT5, MAPK-1, P53) and protein levels were analyzed by real-time PCR and Western blotting.
• Cell proliferation was measured using the MTT assay.

Main Results:

• Successful nano-drug delivery into HT-29 colon cancer cells was confirmed.
• Significant downregulation of EGFR, c-Src, STAT5, MAPK-1, and P53 gene expression was observed.
• Reduced protein expression of EGFR and c-Src was demonstrated.
• A notable reduction in HT-29 cell proliferation occurred after 48 hours of treatment.

Conclusions:

• The developed nano-drug effectively delivered antisense agents into colon cancer cells.
• Simultaneous inhibition of EGFR and c-Src via antisense technology shows promise for colon cancer treatment.
• Downregulation of key oncogenes and their downstream pathways suggests a potential therapeutic strategy for colon cancer growth inhibition.